These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 378673)

  • 21. Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure.
    Giardina EG; Heissenbuttel RH; Bigger JT
    Ann Intern Med; 1973 Feb; 78(2):183-93. PubMed ID: 4683748
    [No Abstract]   [Full Text] [Related]  

  • 22. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Procainamide in the dog: antiarrhythmic plasma concentrations after intravenous administration.
    Papich MG; Davis LE; Davis CA
    J Vet Pharmacol Ther; 1986 Dec; 9(4):359-69. PubMed ID: 3806778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic studies of procainamide given intermittently intravenously in patients with severe ventricular arrhytmias.
    Wierzchowiecki M; Jasiński K; Trojanowicz R; Ochotny R; Tomaszkiewicz T
    Cor Vasa; 1978; 20(3):176-83. PubMed ID: 688755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
    Piergies AA; Ruo TI; Jansyn EM; Belknap SM; Atkinson AJ
    Clin Pharmacol Ther; 1987 Jul; 42(1):107-12. PubMed ID: 2439251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiarrhythmic potency of procainamide and N-acetylprocainamide in rabbits.
    Minchin RF; Ilett KF; Paterson JW
    Eur J Pharmacol; 1978 Jan; 47(1):51-6. PubMed ID: 618730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-Acetylprocainamide kinetics and clinical response during repeated dosing.
    Rodman JH; Hurst A; Gaarder T; Cohen J; Jelliffe RW
    Clin Pharmacol Ther; 1982 Sep; 32(3):378-86. PubMed ID: 6179685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels.
    Karlsson E
    Br Heart J; 1975 Jul; 37(7):731-40. PubMed ID: 1098684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias.
    Kluger J; Drayer D; Reidenberg M; Ellis G; Lloyd V; Tyberg T; Hayes J
    Am J Cardiol; 1980 Jun; 45(6):1250-7. PubMed ID: 6155064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiarrhythmic drug effect assessed from ventricular arrhythmia reduction in the ambulatory electrocardiogram and treadmill test: comparison of propranolol, procainamide and quinidine.
    Winkle RA; Gradman AH; Fitzgerald JW
    Am J Cardiol; 1978 Sep; 42(3):473-80. PubMed ID: 685858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of the acetylation phenotype and the therapeutic effect of procainamide.
    Schröder P; Klitgaard NA; Simonsen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):63-8. PubMed ID: 84761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia.
    Somberg J; Wynn J; Miura D; Torres V; Williams S; Keefe D
    Angiology; 1986 Dec; 37(12 Pt 2):972-81. PubMed ID: 2433972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arrhythmia control by selective lengthening of cardiac repolarization: role of N-acetylprocainamide, active metabolite of procainamide.
    Singh BN; Feld G; Nademanee K
    Angiology; 1986 Dec; 37(12 Pt 2):930-8. PubMed ID: 2433967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Procainamide toxicity in a patient with acute renal failure.
    Rosansky SJ; Brady ME
    Am J Kidney Dis; 1986 Jun; 7(6):502-6. PubMed ID: 2424305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrophysiologic effects of N-acetylprocainamide in human beings.
    Jaillon P; Rubenson D; Peters F; Mason JW; Winkle RA
    Am J Cardiol; 1981 May; 47(5):1134-40. PubMed ID: 6164285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative evaluation of procainamide and its main metabolite, N-acetylprocainamide, in the acute treatment of ventricular arrhythmias [proceedings].
    Karlsson E; Sonnhag C
    Br J Clin Pharmacol; 1977 Oct; 4(5):632P. PubMed ID: 911617
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative electrophysiologic effects of intravenous and oral procainamide in patients with sustained ventricular arrhythmias.
    Marchlinski FE; Buxton AE; Vassallo JA; Waxman HL; Cassidy DM; Doherty JU; Josephson ME
    J Am Coll Cardiol; 1984 Dec; 4(6):1247-54. PubMed ID: 6209319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia].
    Sinkiewicz W; Marzec A; Jankowski A; Hoffmann A; Makuch K; Romański B
    Pol Tyg Lek; 1990 Jun 4-11; 45(23-24):458-60. PubMed ID: 1703654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.